Sun Pharma Advanced Research is Safe Investment
Sun Pharma Advanced Research
Visit Amazon Please
Visit the Link Please
- Pharma Industry Should be Protected From Foreign Takeover | Socyberty
Foreign companies are standing in the beeline to takeover Indian pharmaceutical companies. Will the drug prices shoot up because of this?
Your Vote Please
Will you buy the shares of Sun Pharma Advanced Research at the current price?See results without voting
Sun Pharma Advanced Research - position in NSE
Deliverable Quantity (gross across client level)
% of Deliverable Quantity to Traded Quantity
Test your knowledge
Good Quarterly Results
Good Quarterly Results
Sun Pharma Advanced Research has produced a good second quarter results ended 30.09.11. Total income increased to Rs.1894 crore from Rs.1331 crore in the corresponding period of the previous year. Net profit increased to Rs.597 crore from Rs.503 crore in the corresponding period of the previous year. Paid-up capital of the company stood at Rs.103 crore. Free reserves stood at Rs.9379 crore at the end of last year. The book value of the company is quite high. The shares of Sun Pharma Advanced Research are traded in the Indian stock exchanges at Rs.82.60 (NSE 17.01.12). The face value of the company’s shares is Rs.1.
US Business Is Bright
The company’s US business is on a bright note. Taro Pharmaceuticals is doing well in USA. The company obtained six approvals and has filed for five more. The total number of awaiting approval stands at 150. The company’s Registered Office is located at Tandalia, Vadodara 390020 in Gujarat State in India. Its Corporate Office is located at Acme Plaza, Andheri-Kurla Road, Andheri East, Mumbai 400059.
Tax Provision Increases Steeply
The company’s total expenditure increased to Rs.1177 crore from Rs.899 crore in the corresponding period of the previous year. Other income has increased from Rs.55 crore to Rs.76 crore. Tax expenditure has increased from Rs.17 crore to Rs.128 crore. Interest expenditure increased from Rs.3 crore to Rs.109 crore. Employee cost increased from Rs.145 crore to Rs.272 crore. Depreciation increased from Rs.35 crore to Rs.66 crore.
Safe Investment at Current Market Price
Public hold around 36% of the company’s shares. The company belongs to the reputed Sun Pharma group which is the number one pharmaceutical company in India among Indian companies. Investors can safely buy the shares of Sun Pharma Advanced Research at the current market price for medium and long term holding for decent gains.
More by this Author
Air coolers are best suited to people living in the interior away from the sea. For those who live within fifty kilometres of sea coast, air coolers are difficult to maintain and they should opt for air conditioners....
No comments yet.